Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company’s lead product candidate is Fampridine-SR, which is in a Phase III clinical trial for the improvement of walking ability in people with multiple sclerosis. Its preclinical programs comprise remyelination programs that include two distinct...